Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciBase Holding AB's gross profit for the
three
months ended in Mar. 2026 was kr7.03 Mil. SciBase Holding AB's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was kr26.91 Mil.
SciBase Holding AB (OSTO:SCIB) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
SciBase Holding AB had a gross margin of 49.20% for the quarter that ended in Mar. 2026 => Durable competitive advantage
SciBase Holding AB Gross Profit Related Terms
SciBase Holding AB Gross Profit Historical Data
* Premium members only.
The historical data trend for SciBase Holding AB's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SCIB vs ABT, SYK, MDT: Gross Profit Comparison
For the Medical Devices subindustry, SciBase Holding AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's Gross Profit distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr26.91 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
SciBase Holding AB (OSTO:SCIB) has a Gross Profit of kr26.91 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on SciBase Holding AB and its competitors.
Is SciBase Holding AB's Gross Profit too high?
SciBase Holding AB's current Gross Profit is kr26.91 Mil. Overall, SciBase Holding AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's Gross Profit compare to ABT and SYK?
SciBase Holding AB's Gross Profit of kr26.91 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on SciBase Holding AB and its competitors. SciBase Holding AB's current Gross Profit is kr26.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Significantly Overvalued. The stock's GF Value™ is kr20.19, compared to a current price of kr27.90 — trading 38.2% above its estimated fair value. The current Gross Profit is kr26.91 Mil. SciBase Holding AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current Gross Profit is kr26.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?
Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued.
The current stock price of kr27.90 is trading 38.2% above its estimated GF Value™ of kr20.19.
GuruFocus considers SciBase Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:SCIB:
Gross Profit: kr26.91 Mil
GF Value™: kr20.19 vs. price of kr27.90 (38.2% above fair value)
No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
47GF Score
Get the complete analysis for OSTO:SCIB
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SCIB has been successfully added to your 
